PLCG2 is determined as a potential indicator of TME remodeling in tumor, and dysfunction of PLCG2 is closely associated with inflammation, immune disorders, and cancer (Koss et al., 2014; Li et al., 2021b). This evidence concerns the gene PLCG2 and cancer.